Biomedical Engineering Reference
In-Depth Information
(a)
1500
Control
CA074Me
1000
*
500
0
7 Days
7 Days
(b)
1500
Control
CA074Me
1000
500
*
0
7 Days
7 Days
(c)
1500
Control
CA074Me
1000
*
*
500
0
7 Days
7 Days 30 Days 30 Days
Figure 6.5
CA074Me reduces brain Ab in guinea pigs: a natural model of human WT
APP processing at the b-secretase site. (a) Brain Ab40 is reduced by
CA074Me administered to guinea pigs. CA074Me was administered to
guinea pig brains for 7 days by intracerebroventricular mini-pump infu-
sion. After this treatment, brain levels of Ab40 were measured. Results
show substantial reduction in Ab40 by 47% (*statistically significant,
p
o
0.05, Student's t-test). (b) Brain Ab42 is reduced by CA074Me admi-
nistered to guinea pigs. After intracerebroventricular administration of
CA074Me, as described in part (a), brain levels of Ab42 were measured.
Results show a significant reduction in Ab42 by 56% (*statistically sig-
nificant, p
o
0.05, Student's t-test). (c) Ab (total) is reduced in synapto-
somal nerve terminals after treatment of guinea pigs with CA074Me. After
administration of CA074Me to guinea pigs by intracerebroventricular
infusion, synaptosomes were prepared and Ab (total was measured in this
preparation of nerve terminals). The results show that CA074Me reduced
Ab by 50-70% (*statistically significant, p
o
0.05, Student's t-test).
